Keytruda (pembrolizumab) v indikácii podľa klinického skúšania KN590 - ca pažeráka

Organisation: Merck Sharp & Dohme, s.r.o.

Created at: 26.03.2025

Processed at: 02.04.2026

Question

Please include Keytruda (pembrolizumab) in the case of a final decision of the Ministry of Health of the Slovak Republic from 1.1.2026 in the DRG as a creditable item

on - ID35033 is pending in the indication in question, with an expected date of inclusion in the ZKL in 2025

patients with oesophageal cancer requiring first-line treatment for locally advanced, unresectable or metastatic cancer during hospitalisation

Answer

The indication restrictions (IOs) in the DRG system are aligned with the IOs that are listed in the categorisation list of medicines. As the SK-DRG system is updated only once a year and new indications enter the categorisation list all year round, in order to avoid misalignment of the two systems, the reporting of indication restrictions has been transferred to marker reporting, which makes the DRG system more flexible and as soon as a medicine is categorised under a new indication, it can also be reported under the DRG system.